Designing Smarter Neurology Clinical Trials with Real-World Data & Protocol Optimization

By Sonick Suri

Clinical trial protocols are designed with scientific precision but rarely with population-level evidence. NeuroDiscovery AI changes that. Using the largest neurology real-world dataset in the United States, we help sponsors identify where their protocol will break down before the first patient is ever screened. Built for pharma sponsors, biotech teams, and clinical development organizations running trials across neurology from common neurological conditions to rare and ultra-rare CNS indications.

Designing Smarter Neurology Clinical Trials: A Protocol Optimization Approach Built on Real-World Data

Clinical development teams spend months crafting eligibility criteria balancing scientific rigor, regulatory precedent, and safety margins. What rarely enters that process is a simple, data-driven question: do enough patients actually exist to make this trial work?

In neurology, that question is more consequential than almost any other therapeutic area. Patient populations are smaller, diagnostic pathways are longer, and the gap between a patient who carries a diagnosis and a patient who meets full trial eligibility is often wider than sponsors expect. The downstream effects are well-documented and expensive:

• Across all therapeutic areas, an estimated 80% of clinical trials fail to meet their original enrollment timelines [1] and in neurology specifically, screen failure rates run even higher than the cross-therapeutic average, compounding the delay.

• Enrollment delays can cost sponsors between $600,000 and $8 million in lost revenue per day for late-stage assets [2] the larger figure reflecting the commercial exposure of a delayed launch for a high-value therapy.

• The median direct cost to implement a single substantial protocol amendment is $535,000 for a Phase III protocol ($141,000 for Phase II) and the majority of trials require more than one [3].

• Neurological and CNS trials carry an average screen failure rate of 57%, compared with 36.3% across all therapeutic areas, nearly double in some Alzheimer's disease trials, where screen failure can exceed 80% [4].

The answer is not to weaken eligibility standards. It is smarter protocol design, informed by real-world data from the start.

“Eligibility criteria written without population evidence are hypotheses. We test them before your trial does.”

The Data Behind the Difference

NeuroDiscovery AI operates the largest neurology-focused real-world dataset in the United States longitudinal EHR data spanning structured diagnoses, lab values, medication histories, imaging records, and unstructured clinical notes across a nationally representative patient population.

This is not Claims data. It is not a static registry. It is the actual clinical record of the patients your sites will be trying to enroll and it gives our clinical trial protocol optimization engagements a depth of precision that no competitor in the neurology space can match.

What our dataset covers

• Structured diagnoses mapped to ICD-10, longitudinal and timestamped

• Lab and biomarker results with platform and unit-level detail

• Medication history including status and durations

• Unstructured neurology progress notes with NLP-extracted clinical features

• Imaging and procedure records across inpatient and outpatient settings

What this enables

• Real patient counts not modeled estimates at every criterion step

• Criterion-level break-point identification before protocol lock

• Scenario modeling with quantified enrollment impact per proposed change

• Competitive landscape analysis against the same patient pool your sites will screen

How Clinical Trial Protocol Optimization Works

We engage at the earliest viable point before protocol finalization and work through three interconnected phases. The goal at each phase is the same: replace assumption with evidence.

Phase 1: Feasibility Diagnosis

We begin with a structured review of your draft protocol, cataloguing every inclusion and exclusion criterion and tagging each for complexity compound logic, biomarker dependencies, time-sensitive observation windows. Each criterion then receives a data-driven complexity score across three measurable dimensions:

• Structured capture rate- what proportion of your target cohort has this data point reliably documented in structured EHR fields

• Single-criterion pass rate- what proportion of the indication population clears this criterion in isolation

• Marginal attrition- the additional drop in eligible patients caused specifically by adding this one criterion on top of a cohort that has already cleared every other criterion. In effect, it isolates the impact of removing or relaxing just this single requirement, holding everything else constant.

The output is a ranked criteria scorecard that tells you, before a single query hits a site database, exactly where your enrollment risk lives.

Phase 2: Population Modeling & Competitive Pressure

With the scorecard in hand, we run your full eligibility criteria as a sequential cohort funnel against live EHR data. Patient counts are calculated at every criterion step. We identify the precise break point, the criterion or combination where the eligible pool collapses below what your enrollment target requires.

We then layer on the competitive context. Using ClinicalTrials.gov data, we identify every active or recruiting trial that overlaps your indication and patient profile, assess criteria overlap, and estimate how much of your eligible population is already being pursued. In neurology where competing trials often draw from the same limited patient pool this intelligence frequently reshapes site strategy before a single site is activated.

Phase 3: Scenario Modeling & Sponsor Decision

For every bottleneck criterion identified, we model alternative definitions and quantify the enrollment impact of each modification against our dataset. Adjusted thresholds, relaxed age boundaries, expanded lookback windows, validated clinical proxies for hard-to-capture biomarkers each scenario is run, measured, and presented in a structured trade-off matrix.

The sponsor decides. We provide the evidence to make that decision with confidence rather than intuition.

Following sponsor review, we run a final feasibility confirmation against the revised criteria producing a documented, data-backed enrollment baseline that travels with the protocol into site activation.

Your Protocol, De-Risked

Deliverable	What it tells you
Criteria complexity scorecard	Every criterion ranked by computed restrictiveness, data availability, prevalence, and marginal attrition
Real-world cohort funnel	Patient counts at each criterion step with break-point identification
Competitive landscape report	Active trial overlap and estimated patient pool contention in your indication
Scenario comparison table	Enrollment impact quantified per proposed criterion modification
Trade-off matrix	Scientific and regulatory considerations mapped against operational gain for each scenario
Final feasibility memo	Post-revision confirmation against revised criteria, suitable for internal planning and site briefing

The Earlier You Engage, The More We Can Change

Optimal engagement window Pre-IND or pre-amendment before protocol lock. This is the one point in development where meaningful criteria changes are possible without regulatory disruption or the major cost implications of a post-lock amendment. Post-lock engagements are still valuable, but the scope of actionable change narrows significantly. The earlier we engage, the greater the return.

Criteria that are fixed due to regulatory precedent, prior trial comparability, or scientific non-negotiables are preserved as hard constraints scenario modeling applies only to the flexible criteria set. Criteria that depend on data types with limited EHR representation (patient-reported outcomes, rare genomic markers) are flagged explicitly, with feasibility estimates treated as directional upper bounds.

The Neurology Difference

Clinical trial Protocol optimization is not new. What is new and what no other partner delivering neurology clinical trials offers is doing it against a dataset purpose-built for neurology at national scale. The nuances that matter in neurological disease are not abstract: agitation status buried in unstructured notes rather than structured fields, biomarker results that vary by platform, These are the patterns we built to detect. They are the core of what we built for.

When NeuroDiscovery AI runs your cohort funnel, the patients in that analysis are the same patients your sites will screen. That is the difference between a feasibility estimate and a feasibility guarantee.

Let's Look at Your Protocol If your team is in protocol development or considering an amendment we can typically complete an initial feasibility diagnosis within two to three weeks of receiving a draft. The analysis does not require a finalized protocol, and early-stage drafts often yield the most actionable findings. Connect with the NeuroDiscovery AI Clinical Informatics team to schedule a protocol review.

FAQs

What is clinical trial protocol optimization using real-world evidence?
Clinical trial protocol optimization using real-world evidence means testing a trial's eligibility criteria against actual patient data before the protocol is finalized, rather than relying only on clinical judgment and precedent. Instead of estimating how many patients might qualify for a trial, sponsors can see real counts of how many patients in a given population actually meet each criterion, and where the eligible pool narrows fastest.

How is this different from a traditional feasibility assessment?
Traditional feasibility assessments typically rely on site surveys, investigator estimates, or modeled projections from smaller or non-representative datasets. RWE-based feasibility replaces those estimates with criterion-by-criterion patient counts pulled from real, longitudinal clinical records, so sponsors can see exactly which criteria are driving enrollment risk instead of discovering it after sites go live.

What real-world data sources are used, and how is patient privacy handled?
NeuroDiscovery AI's analysis draws on structured EHR data (diagnoses, labs, medication history, imaging) and unstructured clinical notes across a nationally representative neurology patient population. All data used in feasibility modeling is de-identified in compliance with HIPAA and applicable data privacy standards, and no individual patient can be identified from the analysis or resulting reports.

When in the clinical trial lifecycle should sponsors engage for protocol optimization?
The greatest impact comes from engaging before protocol lock ideally pre-IND or before a planned amendment since that's when eligibility criteria can still be adjusted without regulatory disruption or amendment costs. Sponsors can still benefit from a post-lock engagement, but the range of actionable changes narrows once a protocol is finalized.

How long does a feasibility diagnosis take?
An initial feasibility diagnosis can typically be completed within two to three weeks of receiving a draft protocol. A finalized protocol isn't required to begin; in fact, early-stage drafts tend to surface the most actionable findings, since there's more room to act on what the data shows.

What indications does NeuroDiscovery AI's dataset cover?
Our dataset spans the full neurology spectrum, with particular depth in Alzheimer's disease and MCI, epilepsy, Multiple Sclerosis, Parkinson's disease, and rare neurological conditions.

---

References

1. Online Patient Recruitment in Clinical Trials: Systematic Review and Meta-Analysis. JMIR. Reports that around 80% of trials fail to meet initial enrollment targets and timelines. https://pubmed.ncbi.nlm.nih.gov/33146627/

2. Quantitative assessment of the impact of standard agreement templates on multisite clinical trial start-up time. PMC. Estimates of sponsor delay costs ranging from $600,000 to $8 million per day. https://pmc.ncbi.nlm.nih.gov/articles/PMC10565190/

3. Getz, K.A., et al. The Impact of Protocol Amendments on Clinical Trial Performance and Cost. Therapeutic Innovation & Regulatory Science, 2016 (Tufts CSDD). Median direct cost of $535,000 (Phase III) and $141,000 (Phase II) per substantial amendment; 57% of protocols required at least one amendment. https://link.springer.com/article/10.1177/2168479016632271

4. Tackling High Screen Failure Rates and Boosting Diversity in CNS Clinical Trials. Alliance Clinical Network, citing Applied Clinical Trials data. Neurological trial screen failure rate of 57% vs. 36.3% cross-therapeutic average; AD trial screen failure rates of 44% (mild AD) to 88% (preclinical AD). https://allianceclinicalnetwork.com/tackling-high-screen-failure-rates-and-boosting-diversity-in-cns-clinical-trials/

Note: Figures above are drawn from third-party industry research and academic publications, cited for directional context. They are not NeuroDiscovery AI's own outcome data.

---